Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Bought by Intech Investment Management LLC

Intech Investment Management LLC lifted its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 593.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 67,132 shares of the specialty pharmaceutical company’s stock after acquiring an additional 57,455 shares during the quarter. Intech Investment Management LLC owned 0.21% of Collegium Pharmaceutical worth $1,923,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. TD Private Client Wealth LLC increased its position in shares of Collegium Pharmaceutical by 39.5% during the third quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock worth $66,000 after acquiring an additional 483 shares during the period. Virtus Fund Advisers LLC purchased a new stake in shares of Collegium Pharmaceutical during the third quarter worth $72,000. KBC Group NV increased its position in shares of Collegium Pharmaceutical by 72.5% during the fourth quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company’s stock worth $67,000 after acquiring an additional 982 shares during the period. Nisa Investment Advisors LLC increased its position in shares of Collegium Pharmaceutical by 14.5% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock worth $71,000 after acquiring an additional 316 shares during the period. Finally, China Universal Asset Management Co. Ltd. increased its position in shares of Collegium Pharmaceutical by 10.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,838 shares of the specialty pharmaceutical company’s stock worth $196,000 after acquiring an additional 642 shares during the period.

Insider Buying and Selling at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 40,000 shares of the company’s stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $28.08, for a total value of $1,123,200.00. Following the completion of the transaction, the executive vice president now owns 154,204 shares in the company, valued at $4,330,048.32. This represents a 20.60 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Colleen Tupper sold 1,949 shares of the stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $30.00, for a total transaction of $58,470.00. Following the sale, the chief financial officer now owns 177,195 shares of the company’s stock, valued at $5,315,850. This trade represents a 1.09 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 109,193 shares of company stock worth $3,243,594 over the last 90 days. Corporate insiders own 3.98% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. Needham & Company LLC raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price objective on the stock in a research report on Friday, January 10th. HC Wainwright reissued a “buy” rating and issued a $50.00 target price on shares of Collegium Pharmaceutical in a report on Friday, January 10th. Finally, Piper Sandler dropped their target price on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a report on Tuesday, February 4th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $43.60.

Collegium Pharmaceutical Stock Performance

NASDAQ:COLL opened at $29.93 on Friday. The firm has a market capitalization of $942.38 million, a PE ratio of 12.90 and a beta of 0.99. The business’s fifty day moving average price is $30.75 and its 200 day moving average price is $32.77. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. Collegium Pharmaceutical, Inc. has a 12 month low of $27.28 and a 12 month high of $42.29.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.09. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. The company had revenue of $181.95 million during the quarter, compared to the consensus estimate of $179.68 million. On average, sell-side analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.